ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

2:00PM-3:30PM: Abstract Number: 2474

Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

2:00PM-3:30PM: Abstract Number: 2432

Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis

Abstracts: RA – Etiology & Pathogenesis

4:00PM-5:30PM: Abstract Number: 2534

A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

4:00PM-5:30PM: Abstract Number: 2519

A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2546

Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2558

Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2510

Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

Abstracts: Immunological Complications of Medical Therapy

4:00PM-5:30PM: Abstract Number: 2539

Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2547

Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2508

Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts

Abstracts: Cytokines & Cell Trafficking

4:00PM-5:30PM: Abstract Number: 2543

Clinical and Radiographic Results of Tapering and Withdrawing CsDMARDs versus Stable Treatment in Patients with Rheumatoid Arthritis in Remission: 3-year Results from a Randomized Controlled Trial

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2559

Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2557

Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2555

Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

4:00PM-5:30PM: Abstract Number: 2529

Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].